dopamine receptor D2 antagonists (Ricangen)

N/A

Report date: 2025/03/18 20:00:05

NME

Base Information

Drug Namedopamine receptor D2 antagonists (Ricangen)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionDopamine D2 receptor antagonists

TargetsDopamine D2 receptor

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesRicangen

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesRicangen

Active IndicationsN/A

Inactive IndicationsPancreatic Neoplasms

ATC CodeN/A